MannKind Corporation Q3 2025 Earnings Recap

MannKind Corporation reported a record revenue of $82 million in Q3 2025, driven by strong product performance and the recent acquisition of scPharmaceuticals, positioning the company for significant growth ahead.

Key Takeaways

• Q3 2025 revenue reached $82 million, marking a record for the company, with Tyvaso DPI contributing $59 million in royalties and manufacturing revenue.
• The supplemental BLA for Afrezza was accepted for review, with a PDUFA date set for Q2 2026, highlighting potential pediatric market entry.
• FUROSCIX revenue grew by 95% year-to-date compared to 2024, with significant adoption, including over 27,000 doses dispensed in Q3, anticipated to reflect in Q4 results post-acquisition.
• The acquisition of scPharmaceuticals enhances MannKind's commercial scale and accelerates growth into cardiorenal medicine, targeting a substantial market opportunity in heart failure and chronic kidney disease.
• Afrezza prescription growth continued, with a 31% increase in new prescriptions year-over-year, despite a shift in focus towards type 1 diabetes.